Description: Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Home Page: www.acurxpharma.com
ACXP Technical Analysis
259 Liberty Avenue
Staten Island,
NY
10305
United States
Phone:
917-533-1469
Officers
| Name | Title |
|---|---|
| Mr. Robert J. DeLuccia | Co-Founder & Exec. Chairman |
| Mr. David P. Luci CPA, CPA, Esq., J.D. | Corp. Sec., Co-Founder, Pres, CEO & Director |
| Mr. Robert G. Shawah CPA, CPA | Co-Founder & CFO |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3934 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |